Hepatitis C Recurrence Testing and Management

Diagnostic Approach

The American Association for the Study of Liver Diseases recommends HCV RNA testing as the gold standard for detecting active hepatitis C infection and confirming recurrence or reinfection in patients with risk factors 1, 2
HCV core antigen testing can be used as an alternative when HCV RNA testing is not available, though it is less sensitive, and is recommended by the European Association for the Study of the Liver 1, 3
Anti-HCV antibodies persist after viral clearance and cannot be used to determine if hepatitis C has returned, as stated by the American Association for the Study of Liver Diseases 1, 3

The Centers for Disease Control and Prevention suggests that HCV reinfection should be suspected when HCV RNA or HCV core antigen reappears after achieving sustained virologic response (SVR) in individuals with risk factors 1, 3
Assessment for HCV recurrence is only necessary if the patient has ongoing risk for HCV infection or experiences unexplained hepatic dysfunction, according to the American Association for the Study of Liver Diseases 4
A quantitative HCV RNA assay is recommended to test for HCV recurrence or reinfection, as stated by the European Association for the Study of the Liver 4, 5

A positive HCV RNA test indicates active HCV infection, which could be recurrence of the original infection or reinfection with a new strain, as confirmed by the American Association for the Study of Liver Diseases 1, 2
Confirmation of reinfection requires demonstration that the infection is caused by a different genotype or a distantly related strain of the same genotype using sequencing and phylogenetic analysis, according to the European Association for the Study of the Liver 1, 3

For patients with confirmed recurrence (positive HCV RNA), full evaluation for retreatment should be initiated, and assessment of liver disease severity is recommended, as stated by the American Association for the Study of Liver Diseases 4
For patients without recurrence (negative HCV RNA), if no advanced fibrosis was present before treatment, no additional follow-up is recommended, but if advanced fibrosis (F3-F4) was present, continue surveillance for hepatocellular carcinoma with twice-yearly abdominal imaging, according to the European Association for the Study of the Liver 4

The American Association for the Study of Liver Diseases recommends HCV RNA testing performed 12 weeks after completion of antiviral therapy, with undetectable HCV RNA (<15 IU/mL) defining sustained virologic response (SVR12), which indicates cure, in patients with hepatitis C 6

The Centers for Disease Control and Prevention suggests performing quantitative HCV RNA testing at 12 weeks post-treatment (SVR12) to document cure, using an FDA-approved nucleic acid test (NAT) with a lower limit of detection ≤15 IU/mL for optimal sensitivity, in patients who have completed antiviral therapy for hepatitis C 6
The European Association for the Study of the Liver recommends that the same laboratory should ideally be used for pre-treatment and post-treatment testing to ensure consistency, for patients undergoing HCV RNA testing 7

Modern quantitative HCV RNA assays using real-time PCR or transcription-mediated amplification have lower detection limits of 12-15 IU/mL with broad dynamic range (up to 7-8 log IU/mL) and 98-99% diagnostic specificity across all genotypes, according to the Clinical and Molecular Hepatology guidelines 7
The World Health Organization suggests that these assays have replaced older qualitative tests and can serve both diagnostic and monitoring purposes, for patients with hepatitis C 7, 6

The American College of Gastroenterology recommends never relying on anti-HCV antibody testing to confirm cure – antibodies remain positive for years or indefinitely after successful treatment, making them completely unreliable for this purpose, in patients who have completed antiviral therapy for hepatitis C 7, 8
The Centers for Disease Control and Prevention advises against using ALT levels alone to determine treatment success, as liver enzymes can normalize despite persistent viremia or remain elevated from other causes, in patients with hepatitis C 9